Evaluation of the Qtc Interval During Lenvatinib Treatment in Radioiodine-Refractory Differentiated Thyroid Cancer: Reports from the Real-Life Clinical Practice
- DOI
- 10.2217/fon-2019-0096
- Published
- 2019-08-16
- Container
- Future Oncology
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.2217/fon-2019-0096,
title = {Evaluation of the Qtc Interval During Lenvatinib Treatment in Radioiodine-Refractory Differentiated Thyroid Cancer: Reports from the Real-Life Clinical Practice},
author = {Michela Marina and Maria Francesca Serra and Paolo Del Rio and Graziano Ceresini},
year = {2019},
journal = {Future Oncology},
doi = {10.2217/fon-2019-0096},
url = {https://doi.org/10.2217/fon-2019-0096}
}RIS
TY - JOUR TI - Evaluation of the Qtc Interval During Lenvatinib Treatment in Radioiodine-Refractory Differentiated Thyroid Cancer: Reports from the Real-Life Clinical Practice AU - Michela Marina AU - Maria Francesca Serra AU - Paolo Del Rio AU - Graziano Ceresini PY - 2019 JO - Future Oncology DO - 10.2217/fon-2019-0096 UR - https://doi.org/10.2217/fon-2019-0096 ER -
APA
Marina, M., Serra, M. F., Rio, P. D., & Ceresini, G. (2019). Evaluation of the Qtc Interval During Lenvatinib Treatment in Radioiodine-Refractory Differentiated Thyroid Cancer: Reports from the Real-Life Clinical Practice. Future Oncology. https://doi.org/10.2217/fon-2019-0096
Source records
- crossref · retrieved 2026-09-25T12:08:55.223Z